L Bergamaschini

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. doi request reprint Alzheimer's disease: another target for heparin therapy
    Luigi Bergamaschini
    Department of Internal Medicine, Geriatric Unit, Ospedale Maggiore Policlinico IRCCS, University of Milan, Italy
    ScientificWorldJournal 9:891-908. 2009
  2. ncbi request reprint Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease
    Luigi Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore, Instituto di Ricovero e Cura a Carattere Scientifico, University of Milan, 20122 Milan, Italy
    J Neurosci 24:4181-6. 2004
  3. ncbi request reprint Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro
    Luigi Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore IRCCS, University of Milan, Italy
    Neurobiol Aging 23:531-6. 2002
  4. pmc Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver
    L Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore IRCCS, Milan, Italy
    Clin Exp Immunol 126:412-20. 2001
  5. ncbi request reprint Activation of complement and contact system in Alzheimer's disease
    L Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore IRCCS, University of Milan, Via Pace 15, 20122, Milan, Italy
    Mech Ageing Dev 122:1971-83. 2001
  6. ncbi request reprint The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system
    L Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore, IRCCS, University of Milan, Italy
    Neurobiol Aging 22:63-9. 2001
  7. pmc Consumption of C4b-binding protein (C4BP) during in vivo activation of the classical complement pathway
    L Bergamaschini
    Department of Internal Medicine, Maggiore Hospital IRCCS, University of Milan, Milan, Italy
    Clin Exp Immunol 116:220-4. 1999
  8. pmc Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner
    L Bergamaschini
    Department of Internal Medicine, Maggiore Hospital, IRCCS, Milan, Italy
    Clin Exp Immunol 115:526-33. 1999
  9. ncbi request reprint Comparison of two immunoassays for the complement protein C4b-binding protein in health and disease
    R Coppola
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan, Italy
    Int J Clin Lab Res 25:88-92. 1995
  10. ncbi request reprint Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia
    M G De Simoni
    Mario Negri Institute for Pharmacological Research, Milan, Italy
    J Cereb Blood Flow Metab 23:232-9. 2003

Detail Information

Publications10

  1. doi request reprint Alzheimer's disease: another target for heparin therapy
    Luigi Bergamaschini
    Department of Internal Medicine, Geriatric Unit, Ospedale Maggiore Policlinico IRCCS, University of Milan, Italy
    ScientificWorldJournal 9:891-908. 2009
    ....
  2. ncbi request reprint Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease
    Luigi Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore, Instituto di Ricovero e Cura a Carattere Scientifico, University of Milan, 20122 Milan, Italy
    J Neurosci 24:4181-6. 2004
    ..By reducing the beta-amyloid load and cytotoxicity and proinflammatory activity, enoxaparin offers promise as a tool for slowing the progression of Alzheimer's disease...
  3. ncbi request reprint Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro
    Luigi Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore IRCCS, University of Milan, Italy
    Neurobiol Aging 23:531-6. 2002
    ..The present data show that heparin can attenuate neurotoxic and pro-inflammatory activity of Abeta and suggest that this drug could represent a new strategy to reduce the progressive neurodegeneration in AD...
  4. pmc Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver
    L Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore IRCCS, Milan, Italy
    Clin Exp Immunol 126:412-20. 2001
    ..These results suggest that adding C1-INH to the preservation solution may be useful to reduce complement activation and tissue injury during the reperfusion of an ischaemic liver...
  5. ncbi request reprint Activation of complement and contact system in Alzheimer's disease
    L Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore IRCCS, University of Milan, Via Pace 15, 20122, Milan, Italy
    Mech Ageing Dev 122:1971-83. 2001
    ....
  6. ncbi request reprint The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system
    L Bergamaschini
    Department of Internal Medicine, Ospedale Maggiore, IRCCS, University of Milan, Italy
    Neurobiol Aging 22:63-9. 2001
    ....
  7. pmc Consumption of C4b-binding protein (C4BP) during in vivo activation of the classical complement pathway
    L Bergamaschini
    Department of Internal Medicine, Maggiore Hospital IRCCS, University of Milan, Milan, Italy
    Clin Exp Immunol 116:220-4. 1999
    ..The results of this study indicate that C4BP is consumed in vivo during acute, and possibly during chronic activation of the C' classical pathway, and that this protein, after interaction with C4b, not longer circulates in plasma...
  8. pmc Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner
    L Bergamaschini
    Department of Internal Medicine, Maggiore Hospital, IRCCS, Milan, Italy
    Clin Exp Immunol 115:526-33. 1999
    ....
  9. ncbi request reprint Comparison of two immunoassays for the complement protein C4b-binding protein in health and disease
    R Coppola
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan, Italy
    Int J Clin Lab Res 25:88-92. 1995
    ..223 +/- 67%). In these patients crossed immunoelectrophoresis showed a pattern different from that of normal individuals, which may explain the lower values found with the Laurell method...
  10. ncbi request reprint Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia
    M G De Simoni
    Mario Negri Institute for Pharmacological Research, Milan, Italy
    J Cereb Blood Flow Metab 23:232-9. 2003
    ..Astrocyte activation induced by ischemia was not affected by C1-INH. These findings show that C1-INH displayed a potent neuroprotective action by effectively reducing ischemia-reperfusion injury...